SCHEMBL3238487

SCHEMBL3238487

C1CCC(CC[C@H]2CO2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
SIGMAR1 Q99720 3/20 0.39
METAP1 P53582 1/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32
BRCA1 P38398 1/20 0.32
HTT P42858 1/20 0.32
RECQL P46063 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1499255 1.00 CYP1A2 (0.42) CYP1A2SIGMAR1METAP1ALDH1A1HPGD
SCHEMBL825006 0.86 ALDH1A1 (0.40) ALDH1A1TDP1TP53MEN1KMT2A
SCHEMBL13399057 0.86
SCHEMBL903655 0.85 CYP1A2 (0.50) CYP1A2SIGMAR1ALDH1A1TSHR
SCHEMBL11020571 0.85 CYP1A2 (0.50) CYP1A2SIGMAR1ALDH1A1TSHR
SCHEMBL24622845 0.82 ALDH1A1 (0.50) CYP1A2SIGMAR1ALDH1A1TSHR
SCHEMBL23135362 0.80 ALDH1A1 (0.54) CYP1A2SIGMAR1ALDH1A1
SCHEMBL5617552 0.80 CYP1A2 (0.58) CYP1A2SIGMAR1METAP1ALDH1A1HPGD
SCHEMBL60655 0.80 CYP1A2 (0.58) CYP1A2SIGMAR1METAP1ALDH1A1HPGD
SCHEMBL11407095 0.80 CYP1A2 (0.58) CYP1A2SIGMAR1METAP1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745438-B2 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors ELI LILLY AND COMPANY (US) 2010-06-29 US disclosed
EP-2091928-A2 3-(2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2009-08-26 EP disclosed
US-20070225267-A1 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors ELI LILLY AND COMPANY 2007-09-27 US disclosed
WO-2006034093-A2 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS ELLI LILLY AND COMPANY (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225267-A1 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors BACE1, BACE2, APP CYP1A2 198/4885SIGMAR1 2324/4885METAP1 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.